1. Table 2 has been published incorrectly, the correct version is given below:
2. Reference 9 is not correct, the reference should read as follows:
9. Motzer RJ, Escudier B, Tomczak P et al ( Cross-trial comparison of PFS is biased by the fact that in the phase III trial testing everolimus versus placebo (RECORD-1), 53 % of patients progressing on previous targeted therapy had at least one previous therapy, often cytokines. In addition, PFS analysis in this trial was not specifically done for previous sunitinib treatment
